subject area of
- HER2and Responsiveness of Breast Cancer to Adjuvant Chemotherapy Academic Article
- A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial Academic Article
- A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials Academic Article
- A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy Academic Article
- Acute Cardiac Functional and Morphological Changes After Anthracycline Infusions in Children Academic Article
- Adjuvant Chemotherapy for Breast Cancer — 30 Years Later Academic Article
- An unusual class of anthracyclines potentiate Gram-positive antibiotics in intrinsically resistant Gram-negative bacteria Academic Article
- Anthracyclines in Early Breast Cancer Academic Article
- Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer? Academic Article
- Breast carcinoma during pregnancy Academic Article
- Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial Academic Article
- Clinical Practice Guidelines in Cardio-Oncology Academic Article
- Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era? Academic Article
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Academic Article
- Early and late changes in markers of aortic stiffness with breast cancer therapy Academic Article
- Echocardiographic Assessment of Cardiac Function in Pediatric Survivors of Anthracycline-Treated Childhood Cancer Academic Article
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Academic Article
- Epiadryamicin concentration in experimental hepatic metastases after bolus or continous infusion through systemic or locoregional routes. Academic Article
- Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma Academic Article
- HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy Academic Article
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data Academic Article
- HER2/neu in systemic therapy for women with breast cancer: a systematic review Academic Article
- High levels of uPA and PAI-1 predict a good response to anthracyclines Academic Article
- Myocardial Dysfunction Late After Low-Dose Anthracycline Treatment in Asymptomatic Pediatric Patients Academic Article
- Predicting Anthracycline Benefit: TOP2A and CEP17—Not Only but Also Academic Article
- Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial Academic Article
- Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy Academic Article
- Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial Academic Article
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Academic Article
- Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy Academic Article